In addition, blood fasting glucose and electrolyte levels need to be assessed at baseline and during treatment, while evaluation of pituitary function (morning cortisol, ACTH, PRL, gonadotropins, and sex hormones) at baseline is useful for comparison—especially if anti-CTLA-4 is used (hypophysitis can occur within 2–3 months from treatment initiation with anti-CTLA-4, but over 6 months after with anti-PD-1/PD-L1), or in presence of symptoms [10]. This evidence concerns the gene CTLA4 and hypophysitis.